phase 10
ii 7
study 4
belinostat 1
pxd 1
relapsed 7
refractory 7
aggressive 4
bcell 9
lymphomas 6
swog 8
s 4
trial 7
rchop 2
plus 3
bortezomib 5
induction 2
therapy 1
followed 1
maintenance 1
newly 1
diagnosed 1
mantle 4
cell 8
lymphoma 24
evaluation 2
international 1
prognostic 3
score 2
ips 2
simpler 1
advanced 3
hodgkin 2
modern 1
era 3
carfilzomib 1
pr 1
combination 2
vorinostat 1
saha 1
patients 9
intergroup 2
alisertib 1
peripheral 1
tcell 2
transformed 1
mycosis 1
fungoides 1
randomized 1
iii 2
comparing 1
abvd 2
radiotherapy 2
stanford 1
v 1
regimen 1
stages 1
locally 1
extensive 1
bulky 1
mediastinal 1
subset 1
analysis 3
north 1
american 1
e 1
low 1
serum 1
vitamin 1
d 1
levels 1
associated 1
inferior 1
survival 1
follicular 4
prospective 1
lysa 1
studies 1
ibritumomab 1
consolidation 2
cycles 1
chop 2
highrisk 1
limitedstage 1
imexon 1
prooxidant 1
molecule 1
nonhodgkin 2
iodine 1
tositumomab 1
stage 1
diffuse 5
large 5
dlbcl 1
comparative 1
factor 1
models 1
based 1
choprituximab 1
versus 1
iodinetositumomab 1
multicenter 2
hypercvad 1
mtxarac 1
rituximab 7
previously 1
untreated 1
late 1
relapses 1
following 1
highdose 1
autologous 2
stem 2
transplantation 1
hdasct 1
hodgkins 2
hl 1
therapeutic 1
insights 1
biology 1
malignant 1
bendamustine 1
relapsedrefractory 1
indolent 2
outcomes 1
burkitt 1
older 1
age 1
treated 1
intensive 1
chemotherapeutic 1
regimens 1
involved 1
radiation 1
transplant 1
tlr 1
agonist 1
iss 1
immunotherapy 1
results 1
idiotypespecific 1
response 1
support 1
vaccinal 1
effect 1
natural 1
history 1
cns 1
relapse 1
nonhodgkins 2
followup 1
southwest 1
oncology 1
group 1
gemcitabine 1
profound 1
hypogammaglobulinemia 1
years 1
treatment 5
novel 1
concepts 1
radioimmunotherapy 1
b 2
reconstitution 1
recapitulates 1
ontogeny 1
emerging 1
concept 1
antigendriven 1
epidemiology 1
implications 1
advances 1
hematologic 1
malignancies 1
part 2
series 1
nhl 1
